The discovery of hybridoma technology 25 years ago allowed researchers to isolate specifically defined monoclonal antibodies.1 Enthusiasm soared as researchers envisioned in their hands the magic bullet against cancer. Then reality hit: Many obstacles stood in the path toward using monoclonal antibodies as standard therapy. With Food and Drug Administration approval of Herceptin for certain breast cancer tumors last fall and Rituxan for B-cell lymphomas in 1997, cancer researchers have regained
 |
Monoclonal antibodies (MAbs) are analogous to guided missiles homing in on a target. When a foreign invader such as a virus or bacterium enters the body, the immune system produces an array of specific proteins called antibodies. Each plasma cell in the body is responsible for producing one type of antibody only, which acts specifically against a particular antigen, ...
When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.
View this Issue
In this half-day virtual summit, a series of presentations will explore the scientific, regulatory, and operational factors impacting the use of in vitro NAMs in drug discovery.
In this webinar, scientists will discuss innovations that are unlocking new insights into immunity.
In this webinar, Magdalena Pacewicz will highlight how to use AUC to characterize AAVs as part of ensuring regulatory compliance.
Discover how the latest cancer research models and their applications help scientists pursue breakthrough cancer therapy research.
Chief Business Officer Dr. Rob Burgess Shares How Sino Biological Is Empowering Global Biomedical Research Through Precision, Quality, and Innovation on an Exclusive Segment on Fox Business Network airing on February 1, 2026 at 4:30pm EST
Sino Biological, Inc. has announced the accelerated availability and development of critical research tools to support the global scientific community in combating NiV.
Collaboration will bring next generation orchestration and modular automation to scientists worldwide
The ranking places Refeyn among a cohort of high-growth UK technology firms spanning sectors including the life sciences, energy and sustainability, telecommunications, and digital technology.
